Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2021-08-27 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics_PV_AGE4_20210823.pdf
AGM Information Classification · 98% confidence The document is a notarial record (procès-verbal) detailing the proceedings and resolutions of an Extraordinary General Meeting ("ASSEMBLEE GENERALE EXTRAORDINAIRE") of the company "Bone Therapeutics". The content focuses on shareholder voting, quorum verification, and specific resolutions regarding the conditional issuance of subscription rights (Droits de Souscription BEI and Droits de Souscription Patronale Life et Integrale) and associated capital increases. This type of official record documenting shareholder decisions and meeting formalities strongly aligns with the definition of AGM Information, which covers presentations and materials shared during the Annual General Meeting (AGM). Although it is an Extraordinary General Meeting (EGM), the classification AGM-R is the closest fit for formal meeting documentation among the provided codes, as opposed to a simple announcement (RPA/RNS) or a proxy statement (PSI). The length (46,709 chars) confirms it is the full record, not just an announcement.
2021-08-27 French
2EN.Bone Therapeutics_EGM-20210823_Proxy form.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled 'PROXY FORM' and details the process for shareholders to appoint a proxy holder to vote at an 'ordinary general meeting' scheduled for August 23, 2021. It outlines the agenda items, which include resolutions regarding conditional capital increases via warrant issuance and the cancellation of preferential subscription rights. This material is directly related to soliciting shareholder votes and providing necessary information for that purpose, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the final voting result (DVA), nor is it the full Annual Report (10-K) or a general earnings release (ER).
2021-08-06 English
2FR.Bone Therapeutics_AGE-20210823_Procuration.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is titled 'PROCURATION' (Proxy) and details the process for an actionnaire (shareholder) to be represented at an 'assemblée générale extraordinaire' (Extraordinary General Meeting - EGM) scheduled for August 23, 2021. It includes instructions for submitting the proxy form, the agenda items (which heavily involve capital increases via subscription rights issued to the EIB and Patronale Life et Integrale), and voting options. This material is directly related to soliciting shareholder votes and providing necessary information for that purpose, fitting the definition of Proxy Solicitation & Information Statement (PSI). While it concerns an 'assemblée générale', the document itself is the solicitation/proxy form, not the final voting results (DVA) or the general meeting presentation (AGM-R).
2021-08-06 French
1EN.Bone Therapeutics_EGM-20210823_Convening notice.pdf
AGM Information Classification · 98% confidence The document is explicitly titled "INVITATION TO THE EXTRAORDINARY SHAREHOLDERS' MEETING HELD ON 23 AUGUST 2021" and details the agenda, proposed resolutions, and procedures for voting by proxy or in person. This content directly relates to the formal meeting of shareholders, which is the subject matter of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM). Since the document is the invitation and agenda for the meeting itself, and not just the voting results (DVA) or a proxy solicitation material (PSI), the most appropriate classification is AGM-R (AGM Information/Materials). The length (26,305 chars) confirms it is substantial material related to the meeting, not just a brief announcement.
2021-08-06 English
3FR.Bone Therapeutics_AGE-20210823_Information sur les droits des actionnaires.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'INFORMATIONS SUR LE DROIT DES ACTIONNAIRES DE POSER DES QUESTIONS A L'OCCASION DE L'ASSEMBLEE GENERALE EXTRAORDINAIRE' (Information on the right of shareholders to ask questions at the Extraordinary General Meeting). It details the procedures, deadlines (e.g., August 17, 2021), and conditions for shareholders to submit written questions prior to an Extraordinary General Meeting (EGM). This content directly relates to shareholder rights and procedures surrounding a general meeting, which aligns best with the scope of Proxy Solicitation & Information Statement (PSI), as it informs shareholders how to participate and exercise their rights before a vote/meeting. While it mentions the EGM, it is not the final voting results (DVA) nor the formal AGM presentation (AGM-R). It is procedural information for shareholders regarding the meeting.
2021-08-06 French
3EN.Bone Therapeutics_EGM-20210823_Information on shareholders rights.pdf
AGM Information Classification · 98% confidence The document explicitly discusses the rights of shareholders to ask questions in writing prior to an Extraordinary General Meeting (EGM) scheduled for August 23, 2021. It details the conditions for exercising this right (registration date, intent to participate) and the deadline for submitting questions (August 17, 2021). This content is directly related to shareholder participation and procedures surrounding a general meeting, which aligns best with the 'AGM Information' category, even though it is an EGM rather than an AGM, as it concerns meeting procedures and shareholder rights related to the meeting agenda. It is not a proxy statement (PSI) as it doesn't solicit votes, nor is it a declaration of voting results (DVA). Therefore, AGM-R is the most appropriate fit for general meeting procedural information.
2021-08-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.